Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $73

HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $73

HC Wainwright & Co. analyst Joseph Hafling maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $60 to $73.

July 1, 2022

1 minute read

HC Wainwright & Co. analyst Joseph Hafling maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $60 to $73.

JP Morgan Maintains Overweight on Plug Power, Lowers Price Target to $24

January 26, 9:31 AM

JP Morgan analyst Bill Peterson maintains Plug Power (NASDAQ:PLUG) with a Overweight and lowers the price target from $28 to $24.

July 14, 7:31 AM

B of A Securities analyst Julien Dumoulin-Smith upgrades Sempra Energy (NYSE:SRE) from Neutral to Buy.

October 6, 3:28 PM

Within the last quarter, Trex Co (NYSE:TREX) has observed the following analyst ratings:

July 19, 8:44 AM

Truist Securities analyst Michael Ciarmoli maintains AAR (NYSE:AIR) with a Buy and lowers the price target from $58 to $54.